Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ADAG
Adagene Inc.
stock NASDAQ ADR

At Close
Jan 23, 2026 3:59:57 PM EST
2.47USD+21.675%(+0.44)1,990,091
2.45Bid   2.80Ask   0.35Spread
Pre-market
Jan 23, 2026 9:13:30 AM EST
2.02USD-0.493%(-0.01)262
After-hours
Jan 23, 2026 4:52:30 PM EST
2.41USD-2.429%(-0.06)7,003
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
07:20AM EST  Adagene Announces First Patient Dosed With Novel, Proprietary Combination Of Anti-CD137 Agonist, ADG106, And Anti-CTLA-4 Monoclonal Antibody, ADG116   Benzinga
07:00AM EST  Adagene Announces First Patient Dosed with Novel, Proprietary   GlobeNewswire Inc
Jan 19, 2022
07:00AM EST  - Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development-   GlobeNewswire Inc
Jan 13, 2022
11:47AM EST  The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact   Benzinga
04:10AM EST  Adagene Doses First Patients With Advanced NSCLC In Phase 1b/2 Clinical Trial Of ADG106 With Nivolumab In Singapore   RTTNews
04:00AM EST  Adagene Inc. (Adagene) (Nasdaq: ADAG) today announced that the first patients have been dosed in a phase 1b/2 clinical trial of the anti-CD137 agonist antibody, ADG106, in combination with the anti-PD-1 antibody, Nivolumab for patients with advanced non-small cell lung cancer (NSCLC) who have progressed on prior therapies.   GlobeNewswire Inc
Jan 6, 2022
10:11AM EST  Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $27   Benzinga
Dec 26, 2021
09:53AM EST  The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year   Benzinga
Dec 23, 2021
07:29AM EST  The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review   Benzinga
Dec 22, 2021
04:08PM EST  Adagene Reports Achieved Milestone In Its Ongoing Collab With Exelixis For Development Of Novel Masked Antibody-Drug Conjugate Candidates   Benzinga
04:05PM EST  - Successful nomination of lead SAFEbody candidates triggers milestone payment -   GlobeNewswire Inc
Dec 13, 2021
10:25AM EST  Adagene Presents Preclinical Data Showcasing Best-In-Class Profiles For ADG153 And ADG152   Benzinga
10:23AM EST  - Posters presented at the 63rd American Society of Hematology Annual Meeting -   GlobeNewswire Inc
Dec 6, 2021
01:51PM EST  Adagene Presents Clinical Data Co Says Demonstrates Strong Safety, Early Signals Of Efficacy In Cold Tumors Including Pancreatic And Ovarian Cancers For Anti-CTLA-4 Monoclonal Antibody, ADG116, At ESMO-IO 2021   Benzinga
01:50PM EST  Adagene Presents Clinical Data Demonstrating Strong Safety and   GlobeNewswire Inc
Nov 30, 2021
04:47PM EST  The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout   Benzinga
04:28PM EST  Adagene Announces FDA Clearance Of IND For Phase 1b/2 Trial Of Anti-CTLA-4 Monoclonal Antibody ADG116 In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab   Benzinga
Nov 29, 2021
04:05PM EST  Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of   GlobeNewswire Inc
Nov 22, 2021
05:06PM EST  Adagene Announces Poster Presentations of Clinical Data for Two   GlobeNewswire Inc
Oct 27, 2021
07:19AM EDT  Adagene Reports Collab For Trial Of ADG106 In Combo With Nivolumab In Patients With Non-Small Cell Lung Cancer In Singapore   Benzinga
07:00AM EDT  - Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium -   GlobeNewswire Inc
Oct 21, 2021
12:11PM EDT  Adagene To Participate In The Jefferies Virtual China Biotech Summit   Benzinga
Sep 2, 2021
07:45AM EDT  Adagene to Participate at the Morgan Stanley 19th Annual Global   GlobeNewswire Inc
Aug 26, 2021
07:46AM EDT  Adagene 1H EPS $(0.82), Up From $(1.15) YoY   Benzinga
07:45AM EDT  - Established three clinical collaborations with Merck to conduct global combination trialswith pembrolizumab for three clinical-stage oncology candidates -   GlobeNewswire Inc
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
08:16AM EDT  Adagene Inks Third Cancer Trial Collaboration With Merck   Benzinga
07:37AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
07:05AM EDT  Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA   Benzinga
07:00AM EDT  Adagene Announces the Third Clinical Trial Collaboration with   GlobeNewswire Inc
Aug 12, 2021
07:45AM EDT  Adagene Announces Appointment of Interim Chief Medical Officer and   GlobeNewswire Inc
Jul 22, 2021
09:28AM EDT  Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors   Benzinga
07:46AM EDT  Adagene Announces Clinical Trial Collaboration With Merck To Advance Two Anti-CTLA-4 Monoclonal Antibody Programs In Combination Therapy With KEYTRUDA   Benzinga
07:45AM EDT  Adagene Announces Clinical Trial Collaboration With Merck to   GlobeNewswire Inc
Jul 16, 2021
08:01AM EDT  Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $33   Benzinga
Jul 7, 2021
07:46AM EDT  Adagene Announces $20M Buyback   Benzinga
07:45AM EDT  Adagene Announces Authorization of Share Repurchase Program up to   GlobeNewswire Inc
Jun 25, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 25, 2021   Benzinga
05:01AM EDT  China Renaissance Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $40.57   Benzinga
Jun 16, 2021
07:45AM EDT  Adagene Inc. (Adagene) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it will be added to the FTSE Global Equity Index Series (GEIS), including the FTSE Global Total Cap Index and FTSE Emerging Total Cap Index, effective June 21, 2021.   GlobeNewswire Inc
May 25, 2021
04:05PM EDT  Adagene to Present at Upcoming Investor Conferences   GlobeNewswire Inc
May 19, 2021
05:05PM EDT  -Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement   GlobeNewswire Inc
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
07:48AM EDT  Adagene Presents Preclinical Data from Lead SAFEbody Program, ADG126, at the American Association for Cancer Research Annual Meeting 2021   Benzinga
Apr 8, 2021
08:14AM EDT  The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data   Benzinga
Mar 31, 2021
07:46AM EDT  Adagene FY20 Net Loss $42.4M vs ~$16.4M In FY19, Net Sales $700K vs $500K In FY19   Benzinga
07:45AM EDT  - Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds--Reported clinical data for anti-CD137 and two anti-CTLA-4 programs--Advanced five discovery programs into IND-enabling stage--Established multiple academic and industry partnerships--Further strengthened Executive Management team-   GlobeNewswire Inc
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 29, 2021
07:46AM EDT  Adagene Announces Clinical Advancement for ADG116   Benzinga
07:45AM EDT  -NEObody product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial--Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism--Poised for global expansion-   GlobeNewswire Inc
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
Mar 23, 2021
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
Mar 16, 2021
08:12AM EDT  Adagene Reports First Patients Dosed In Global Phase 1 Trial OF ADG126   Benzinga
08:05AM EDT  Adagene Announces First Patients Dosed in Global Phase 1 Clinical   GlobeNewswire Inc
Mar 8, 2021
02:20PM EST  Adagene shares were trading higher after multiple firms initiated coverage on the stock with a bullish rating.   Benzinga
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021   Benzinga
09:28AM EST  Jefferies Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $33   Benzinga
08:04AM EST  Morgan Stanley Initiates Coverage On Adagene with Overweight Rating, Announces Price Target of $34   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 11, 2021
10:08AM EST  Adagene Inc. Announces Closing of Initial Public Offering and   GlobeNewswire Inc
Feb 9, 2021
11:47AM EST  The IPO Week Ahead   Benzinga
09:01AM EST  Adagene Prices 7,354,000 ADS Offering At $19/ADS   Benzinga
09:00AM EST  Adagene Inc. Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC